Keeping you updated on the latest Medicare and Part D news

SCOTUS Opinion: FTC vs Actavis

Leave a comment

This week, the U.S. Supreme Court offered a middle-ground ruling on the issue of reverse payments which allow brand-name drug patent holders to “pay off” generic brand competitors. Whereas the court disagreed with the FTC opinion that such agreements should be automatically illegal, drugmakers like Actavis would likely be required to  prove that drug consumers would not be adversely affected by these agreements.

This article provides some context

SCOTUS Opinion


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s